Current management of muscle-invasive bladder cancer
详细信息 查看全文
- 作者：Gemma Sancho (1)
Pablo Maroto (2)
Joan Palou (3) - 关键词：Infiltrating bladder cancer ; Transurethral resection of the bladder ; Cystectomy ; Radiotherapy ; Chemotherapy
- 刊名：Clinical and Translational Oncology
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：13
- 期：12
- 页码：855-861
- 全文大小：201KB
- 参考文献：1. Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect of recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 58:185鈥?90 CrossRef
2. Solsona E, Iborra I, Ric贸s JV et al (1992) Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: prospective study. J Urol 147:1513鈥?515
3. Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19:89鈥?3
4. Stenzl A, Cowan NC, De Santis M et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 59:1009鈥?018 CrossRef
5. Challacombe BJ, Bochner BH, Dasgupta P et al (2011) The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol 60:767鈥?75 CrossRef
6. Palou J, Gaya JM, Breda A et al (2010) Robotic cystectomy versus open cystectomy: are we there yet? Eur Urol [Suppl 9]:433鈥?37
7. Hellenthal NJ, Hussain A, Andrews PE et al (2010) Surgical margin status after robot assisted radical cystectomy: results from the international robotic cystectomy consortiom. J Urol 184:87鈥?1 CrossRef
8. Hellenthal NJ, Hussain A, Andrews PE et al (2011) Lymphadenectomy at the time of robotassisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int 107:642鈥?46 CrossRef
9. Karl A, Carroll PR, Gschwend JE et al (2009) The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 55:826鈥?35 CrossRef
10. Zehnder P, Studer UE, Skinner EC et al (2011) Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 186:1261鈥?268 CrossRef
11. Roth B, Wissmeyer MP, Zehnder P et al (2010) A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol 57205鈥?7211
12. Hautmann RE, Abol-Enein H, Hafez K et al (2007) World Health Organization (WHO) Consensus Conference on Bladder Cancer. Urology 69[1 Suppl]:17鈥?9 CrossRef
13. Palou J, Baniel J, Klotz L et al (2007) Urothelial carcinoma of the prostate. Urology 69:50鈥?1 CrossRef
14. Menon M, Hemal AK, Tewari A et al (2003) Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int 92:232鈥?36 CrossRef
15. Kessler TM, Burkhard FC, Perimenis P et al (2004) Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol 172:1323鈥?327 CrossRef
16. Finks JJF, Osborne NH, Birkmeyer JD (2011) Trend in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128鈥?137 CrossRef
17. Griffiths G, Hall R, Sylvester R et al (2011) International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: longterm results of the BA06 30894 trial. J Clin Oncol 29:2171鈥?177 CrossRef
18. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859鈥?66 CrossRef
19. Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448鈥?458 CrossRef
20. Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-doseintensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no 30924. J Clin Oncol 19:2638鈥?646
21. Rodel C, Grabenbauer GG, Kuhn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061鈥?071 CrossRef
22. Shipley WU, Kaufman DS, Zehr E et al (2002) Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer urology 60:62鈥?8
23. Perdon脿 S, Autorino R, Daminao R et al (2008) Bladder-sparing, combined modality approach for muscle-invasive bladder cancer. Cancer 112:75鈥?3 CrossRef
24. Tester W, Porter A, Asbell S (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocols 85-12 Int J Radiat Oncol Biol Phys 25:783鈥?90 CrossRef
25. Tester W, Caplan R, Heaney J et al (1996) Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 88-02. J Clin Oncol 14:119鈥?26
26. Efstathiou JA, Bae K, Shipley WU et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27:4055鈥?061 CrossRef
27. Krause FS, Walter B, Ott O et al (2011) 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 31:935鈥?90
28. R枚del C, Weiss C, Sauer R (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24:5536鈥?544 CrossRef
29. Choudhury A, Nelson LD, Teo MTW et al (2011) MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscleinvasive bladder cancer. Cancer Res 70:7017鈥?026 CrossRef
30. Danesie DT, Arcangeli G, Cruciani E et al (2004) Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy and hyperfractionated radiotherapy. Cancer 101:2540鈥?548 CrossRef
31. Hussain SA, Stocken DD, Peake DR et al (2004) Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 90:2106鈥?111
32. Kragelj B, Zaletel-Kragelj L, Sedmak B et al (2005) Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 75:44鈥?7 CrossRef
33. Gogna NK, Matthews JH, Turner SL et al (2006) Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 81:9鈥?7 CrossRef
34. Kaufman D, Winter K, Shipley W (2009) Phase I-II RTOG study (99-06) of patients with muscleinvasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73:833鈥?37 CrossRef
35. Zapatero A, Martin de Vidales C, Arellano R et al (2010) Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 28:368鈥?74 CrossRef
36. Solsona E, Iborra I, Colado A et al (2010) Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184:475鈥?81 CrossRef
37. Stenberg N, Pansadoro V, Calabro F et al (2003) Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 79:1644鈥?652 CrossRef
38. Solsona E, Climent MA, Iborra I et al (2009) Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 55:911鈥?21 CrossRef
39. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder: long-term results in 1054 patients. J Clin Oncol 19:666鈥?75
40. Yossepowitch O, Dalbagni G, Golijanin D et al (2003) Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease. J Urol 169:177鈥?81 CrossRef
41. Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today -a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:660鈥?96 CrossRef
42. Hautmann RE, Gschwend J, de Petriconi RC et al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176:486鈥?92 CrossRef
43. Coppin CM, Gospodarowicz MK, James K et al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation: the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2901鈥?907
44. James N, Hussain S, Hall E et al (2010) Results of a 2x2 phase III randomized trial synchronous chemo-radiotherapy (CRT) compared to radiotherapy (RT) alone and standard vs reduced high volume RT in muscle invasive bladder cancer (MIBC) (BC2001 CRUK/01/0004). Int J Radiat Oncol Biol Phys 78[Suppl]:S2 CrossRef
45. Hoskin PJ, Rojas AM, Bentzen SM et al (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder cancer. J Clin Oncol 28:4912鈥?918 CrossRef
46. Weiss C, Engehausen D, Krause FS et al (2007) Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68:1072鈥?080 CrossRef
47. Shipley WU, Winter KA, Kaufmann DS (1998) Phase III trial on neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576鈥?583
48. Ghersi D, Stewart LA, Parmar MKB et al (1999) Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet 354:533鈥?40 CrossRef
49. Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927鈥?934 CrossRef
50. Zietman AL, Hunt D, Kaufman DS et al (2010) Preliminary results of RTOG 0233: a phase II randomized trial for muscle-invading bladder cancer treated by transurethral resection and radiotherapy comparing two forms of concurrent induction chemotherapy. Int J Radiat Oncol Biol Phys 78[Suppl]:S31 CrossRef
51. Caffo O, Fellin G, Graffer U et al (2011) Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltration bladder cancer. Cancer 117:1190鈥?196 CrossRef
52. Choudhury A, Swindell R, Logue JP et al (2011) Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscleinvasive bladder cancer. J Clin Oncol 29:733鈥?38 CrossRef
53. Cowan RA, McBain CA, Ryder JWD et al (2004) Radiotherapy for muscle-invasive carcinoma of the bladder: results of randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 59:197鈥?07 CrossRef
54. Kaufman DS, Winter KA, Shipley WE (2000) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471鈥?76 CrossRef
55. Hagan MP, Winter KA, Kaufman DS (2003) RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin and adjuvant CMV combination chemotherapy. Int Radiat Oncol Biol Phys 57:665鈥?72 CrossRef
56. Palou J, S谩nchez-Mart铆n FM, Rosales A et al (1999) Intravesical Bacillus Calmatte-Guerin in the treatment of carcinoma in situ or high grade superficial bladder carcinoma after radiotherapy for bladder carcinoma. Br J Urol 83:429鈥?31
57. Piera E, Palou J, Salvador J et al (2003) Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. Eur Urol 44:222鈥?25 CrossRef
58. Zietman AL, Sacco D, Skowronski U et al (2003) Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of urodynamics and quality of life study on long-term survivors. J Urol 170:168鈥?74 CrossRef
59. Shipley WU, Zietman AL, Kaufman DS et al (2004) Selective bladder preservation by trimodality therapy for patients with muscle-invasive bladder cancer and who are cystectomy candidates: the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Radiat Oncol 15:36鈥?1
60. Madersbacher S, Schmidt J, Eberle JM et al (2003) Long-term outcome of ileal conduit diversion. J Urol 169:985鈥?90 CrossRef
61. Studer UE, Burkhard FC, Schumacher M et al (2006)Twenty years experience with an ileal orthotopic low pressure bladder substitute: lessons to be learned. J Urol 176:161鈥?66 CrossRef
62. Huguet J, Monllau V, Sabat茅 S et al (2008) Diagnosis, risk factors and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients. Eur Urol 53:785鈥?93 CrossRef
63. Volkmer BG, Kuefer R, Bartsch GC Jr et al (2009) Oncological follow-up after radical cystectomy for bladder cancer: Is there any benefit? J Urol 181:1587鈥?593 CrossRef
64. Huguet J, Palou J, Mill谩n F et al (2001) Upper tract transitional cell carcinoma following cystectomy for bladder cancer. Eur Urol 40:318鈥?23 CrossRef
65. Mead GM, Russell M, Clark P et al (1998) A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 78:1067鈥?075 CrossRef
66. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050鈥?055
67. Galsky MD, Hahn NM, Rosenberg J et al (2011) Treatment of patients with metastatic urothelial cancer 鈥渦nfit鈥?for cisplatin-based chemotherapy. J Clin Oncol 10:2432鈥?438 CrossRef
68. Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506鈥?13 CrossRef
69. Petrioli, Frediani B, Manganelli A et al (1996) Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77:344鈥?51 CrossRef
70. Bellmunt J, Ribas A, Eres N et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966鈥?972 CrossRef
71. Dogliotti L, Carteni G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase II trial. Eur Urol 52:134鈥?41 CrossRef
72. Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50鈥?4 CrossRef
73. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068鈥?077
74. Bellmunt J, von der Maase H, Mead GM et al (2007) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy鈥?EORTC30987/Intergroup Study. J Clin Oncol 25[Suppl]:242s, abstr LBA5030
75. De Santis M, Bellmunt J, Mead G et al (2009) Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer 鈥渦nfit鈥?for cisplatin-based chemtherapy: phase II-results of EORTC Study 30986. J Clin Oncol 27:5634鈥?639 CrossRef
76. Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173鈥?181
77. Von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602鈥?608 CrossRef
78. Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454鈥?461 CrossRef - 作者单位：Gemma Sancho (1)
Pablo Maroto (2)
Joan Palou (3)
1. Radiation Oncology Department Hospital de la Santa Creu i Sant Pau IIB Sant Pau, Universitat Aut貌noma de Barcelona, C/ Sant Quint铆, 89, ES-08025, Barcelona, Spain
2. Medical Oncology Department Hospital de la Santa Creu i Sant Pau IIB Sant Pau, Universitat Aut貌noma de Barcelona, Barcelona, Spain
3. Department of Urology Fundaci贸 Puigvert, Universitat Aut貌noma de Barcelona, Barcelona, Spain
文摘
Management of muscle-invasive bladder cancer (MIBC) has changed little in the last twenty years. The gold standard treatment is still cystectomy, but it has a significant negative impact on quality of life. Bladder-preservation strategies can be used in some cases but patient selection for this approach remains unclear. New chemotherapy and biologic agents in combination with surgery or radiotherapy could improve results and these possibilities are currently under investigation.